Allogenic Dermis Construct Helps Skin Regenerate

It is manufactured using patented dCELL technology, which maintains the essential structure of the native extracellular matrix (ECM) and preserves a high degree of natural tissue’s biomechanical properties. The remaining decellularized tructure forms a natural scaffold into which a patient’s cells can grow once it is placed onto a wound. Since Dermapure has a distinct outer basement membrane and an inner dermal surface, correct orientation is all important.

A trial in the United Kingdom has shown that patients who had had chronic wounds for an average of 4.5 years and who were treated with a single application of DermaPure saw an 87% reduction in the size of all wounds, while 60% of patients were completely healed, with virtually no recurrences. DermaPure is a product of Tissue Regenix (TRX; York, United Kingdom; www.tissueregenix.com), and does not require refrigeration or rehydration prior to use, making it suitable for use in a variety of healthcare settings, such as hospitals, community clinics, field stations, and doctors’ offices.

“DermaPure is initially being targeted at acute care patients with diabetic foot ulcers, a condition which affects around 600,000 people in the United States, and patients with venous leg ulcers, which currently affect around 2.5 million people,” said Greg Bila, president of TRX. “We see this as a large market that is in need of medical innovation, which is exactly what DermaPure provides.”

dCELL technology uses low concentration processing reagents, including sodium dodecyl sulfate (SDS), DNase, RNase, and glycerol; proteinase inhibitors are used to preserve tissue structure. The preparation process also exposes the skin to antibiotics‐‐penicillin, streptomycin, nystatin, gentamicin, vancomycin, imipenem, and polymixin B. The tissue is then treated to reduce the residual content of reagents.

Related Links:
Tissue Regenix